Antimycobacterial agent-18

Antimycobacterial agent-18 (Compound 7) potently inhibits growth of Mycobacterium smegmatis (MIC = 15.63 μg/mL), M. aurum (MIC = 31.25 μg/mL), M. avium (MIC = 15.63 μg/mL), M. kansasii (MIC = 7.81 μg/mL), Mtb H37Ra (MIC = 1.98 μg/mL), and Mtb H37Rv (MIC = 6.25 μg/mL)^[1].
Antimycobacterial agent-18 (14-21 days) retains activity against multiple drug-resistant Mtb clinical isolates, with MIC values ranging from 3.13 μg/mL to 87.29 μg/mL, and inhibits naturally resistant M. abscessus with an MIC of 25 μg/mL^[1].
Antimycobacterial agent-18 (28 days) does not exhibit reduced potency against Mtb H37Ra strains overproducing FAS II enzymes InhA or HadABC, confirming its mechanism of action is unrelated to the FAS II system^[1].
Antimycobacterial agent-18 (24 h) has low cytotoxicity in HepG2 cells (IC₅₀ = 106.1 μM) with favorable selectivity indices for Mtb H37Ra (SI = 18.71) and Mtb H37Rv (SI = 5.92), and higher cytotoxicity in HK-2 cells (IC₅₀ = 59.1 μM)^[1].
Antimycobacterial agent-18 (3.91-500 μM; 1 h) induces significant hemolysis of human erythrocytes only at 500 μM, exhibiting a far favorable erythrocyte safety profile^[1].
Antimycobacterial agent-18 (1-100× MIC) inhibits fatty acid and derived lipid biosynthesis in Mtb H37Ra, without affecting mycolic acid, TDM, or TMM synthesis, consistent with interference with the FAS I system^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.